Rykindo (Risperidone LAI): How This Every-2-Week Injection Works and When Telehealth Helps

Last updated: August 26, 2026

Rykindo (risperidone) is a long-acting intramuscular injection of extended-release microspheres. A healthcare professional gives it in the gluteal muscle once every 2 weeks. It is not a daily tablet. It is not subcutaneous like Perseris or Uzedy. You establish that you tolerate oral risperidone first. The U.S. label starts many adults at 25 mg every 2 weeks. People who do not respond may move to 37.5 mg or 50 mg. Dose increases should not happen more often than every 4 weeks. The maximum labeled dose is 50 mg every 2 weeks. The first injection is given with 7 days of oral risperidone.

See if online depression or mood care may be a fit →

Browse Klarity condition pages →

TLDR

• Rykindo is intramuscular risperidone LAI (gluteal muscle only), given by a clinician every 2 weeks.
• Labeled for schizophrenia in adults and for maintenance treatment of bipolar I disorder in adults (alone or with lithium or valproate).
• Not approved for dementia-related psychosis. Boxed warning: increased mortality in elderly patients with dementia-related psychosis.
• DailyMed RYKINDO setid 58534c96; label updated May 26, 2026. Packager: Shandong Luye Pharmaceutical Co., Ltd. DEA schedule: none. Initial U.S. approval year on the label: 1993 (risperidone as a molecule). Recent major changes to Dosage and Administration (2.6, 2.7): January 2026.
• Kit strengths: 25 mg, 37.5 mg, and 50 mg.
• Recommended start: 25 mg IM every 2 weeks. Titrate no more often than every 4 weeks. Do not exceed 50 mg every 2 weeks.
• Give the first Rykindo dose with 7 days of oral risperidone. Establish oral risperidone tolerability before the first shot.
• Renal or hepatic impairment: titrate oral risperidone up to at least 2 mg before starting Rykindo.
• Telehealth can support evaluation, oral risperidone trials, labs, and follow-up. A licensed clinician still has to mix and give the gluteal injection in person.
• Coverage may vary by plan. Verify benefits before you book. Klarity has 2,000+ licensed providers.

Table of contents

• What Rykindo is
• How it works
• FDA-labeled uses
• Rykindo dosage
• Side effects and warnings
• Interactions and who should not use it
• How it compares with Perseris, Uzedy, and Risperdal Consta
• When telehealth is enough
• How a Klarity visit fits
• FAQ

What Rykindo is

Rykindo is risperidone for extended-release injectable suspension, for intramuscular use. DailyMed lists it as an atypical antipsychotic kit. Packager: Shandong Luye Pharmaceutical Co., Ltd. Marketing status: New Drug Application. It is not a controlled substance.

The molecule first reached U.S. patients as oral risperidone in 1993. Rykindo is Luye’s microsphere depot. Luye’s January 15, 2023 announcement states FDA approved Rykindo for adult schizophrenia and for bipolar I maintenance (monotherapy or adjunct to lithium or valproate), given IM every two weeks. Drugs.com’s approval history records the same January 2023 decision and notes the every-two-week intramuscular schedule.

Related Klarity guides: Perseris (risperidone LAI), Uzedy (risperidone LAI), and Risperdal (risperidone).

This article is education. It is not a diagnosis and it is not a promise that any clinician will prescribe Rykindo.

How it works

Risperidone blocks dopamine D2 and serotonin 5-HT2A receptors, among other receptor effects. That profile can reduce hallucinations, delusions, and disorganized thinking when a clinician judges it appropriate. Rykindo uses extended-release microspheres so plasma risperidone stays in range between every-2-week clinic visits instead of depending on a daily tablet.

The medicine still carries the same class risks as other risperidone products: movement effects, metabolic change, prolactin elevation, orthostasis, and the boxed dementia-related psychosis warning. A long-acting shot does not make those risks disappear. It changes how you take the drug and how long it stays in your system if you stop.

FDA-labeled uses

Per DailyMed indications, Rykindo is indicated:

• for the treatment of schizophrenia in adults
• as monotherapy or as adjunctive therapy to lithium or valproate for the maintenance treatment of bipolar I disorder in adults

It is not approved for dementia-related psychosis. Off-label uses require a documented clinical rationale and are not a substitute for the label.

Rykindo dosage

Always follow the dose your prescriber writes. DailyMed highlights:

• Establish tolerability with oral risperidone before the first Rykindo injection if you have never taken risperidone.
• A healthcare professional gives the intramuscular injection in the gluteal muscle. Do not give it by any other route.
• Recommended dosage is 25 mg IM every 2 weeks. Patients not responding to 25 mg may benefit from 37.5 mg or 50 mg.
• Do not titrate more often than every 4 weeks. Do not exceed 50 mg every 2 weeks.
• Give the first Rykindo dose along with 7 days of oral risperidone.
• Renal or hepatic impairment: titrate oral risperidone up to at least 2 mg before initiating Rykindo.

Kit strengths on the label: 25 mg, 37.5 mg, and 50 mg. Preparation of the microsphere kit matters. Failure to mix and inject as directed can deliver the wrong dose.

Side effects and warnings

Boxed warning. Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. Rykindo is not approved for that use. See the full boxed warning on DailyMed.

Other label warnings include cerebrovascular events in elderly patients with dementia-related psychosis, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), hyperprolactinemia, orthostatic hypotension and syncope, leukopenia/neutropenia/agranulocytosis, cognitive and motor impairment, and seizures. A clinician watches labs, weight, movement symptoms, and blood pressure over time.

If you have thoughts of suicide or feel you may harm yourself, call or text 988 (Suicide & Crisis Lifeline) or go to the nearest emergency department.

Interactions and who should not use it

Do not use Rykindo if you have known hypersensitivity to risperidone, paliperidone, or any component of the kit. Paliperidone is the active metabolite of risperidone, so a prior reaction to Invega products can matter.

Risperidone is metabolized in part by CYP2D6. Strong CYP2D6 inhibitors and other interacting medicines can change levels. Share a full medication list, including over-the-counter products, with the prescriber. Do not start or stop interacting drugs without a plan.

How it compares with Perseris, Uzedy, and Risperdal Consta

All four products deliver risperidone, but the route and calendar differ:

• Rykindo: IM gluteal, every 2 weeks; 7 days of oral overlap at start; labeled for adult schizophrenia and bipolar I maintenance.
• Perseris: subcutaneous abdomen or back of upper arm, once monthly; no oral overlap after the first shot on the current label; schizophrenia in adults.
• Uzedy: subcutaneous; monthly or every 2 months options; schizophrenia and (on later labeling) bipolar I maintenance.
• Risperdal Consta: older IM microsphere product, also typically every 2 weeks, with a longer oral overlap historically.

Which product fits depends on indication, injection site preference, how often you can come in, oral overlap, and formulary rules. A clinician matches the product to your history. This page does not rank them.

When telehealth is enough

Video psychiatry can evaluate symptoms, review records, start or adjust oral risperidone, order labs, and follow metabolic and movement side effects. It cannot mix the microsphere kit or place a gluteal intramuscular injection. If Rykindo is the plan, you still need an in-person clinician for each shot. Telehealth remains useful between injections for check-ins, co-occurring depression or anxiety care, and benefit questions.

Federal telehealth flexibilities for many Medicare services currently run through December 31, 2027 under HHS policy announced in 2026. State licensing still applies. Coverage may vary by plan.

How a Klarity visit fits

Klarity connects you with 2,000+ licensed providers for online evaluation of mood, psychosis-spectrum symptoms, and related conditions. A visit may cover history, safety, medication options, and whether an oral trial or referral for a long-acting injection makes sense. No clinician can promise Rykindo, any other LAI, or insurance payment in advance.

Coverage may vary by plan. Verify benefits before you book. Typical next steps: confirm the condition page that matches your symptoms, complete an intake, and discuss monitoring if an antipsychotic is appropriate.

See if online depression or mood care may be a fit →

Browse Klarity condition pages →

FAQ

Is Rykindo the same as Risperdal Consta?

Both are intramuscular risperidone microsphere injections given every 2 weeks. They are different products with different manufacturers, kits, and label details. Do not substitute them without a prescriber and pharmacist plan.

Does Rykindo treat bipolar I as well as schizophrenia?

The current DailyMed indications include adult schizophrenia and maintenance treatment of bipolar I disorder in adults as monotherapy or with lithium or valproate. Acute mania programs and other bipolar uses still belong to the clinician and the full label, not a blog post.

Can I get the first injection by telehealth?

No. Rykindo is gluteal IM only, given by a healthcare provider. Telehealth can handle the oral trial, education, and follow-up.

Will insurance cover Rykindo?

Coverage may vary by plan, prior authorization, and whether you have already tolerated oral risperidone. Verify benefits before you book. This article does not state that any plan will cover Rykindo.

Educational content only. Not medical advice. Medications including antipsychotics require an individualized clinical decision. If this is an emergency, call 911. For a mental health crisis, call or text 988.